Insight Molecular (IMDX): Utang-utang marang kapitalisasi buku

Tandha merek imdxinc.com (IMDX)

The optimization of biomaterial logistics supports the high profitability of Insight Molecular Diagnostics (IMDX), as confirmed by the dynamics of the total debt-to-equity ratio. The value of 0.00 expresses the level of this financial stability metric. The development of genetic tests for early diagnosis lays the foundation for personalized treatment, while a restrained ESG policy is based on the proper disposal of laboratory waste and office energy efficiency.

IMDX Rasio utang marang nilai buku Insight Molecular Diagnostics Inc (19.06.2025 - 27.10.2026)
Produk asli Insight Molecular Diagnostics, Inc.

Efficient consumables logistics for Insight Molecular Diagnostics (IMDX) requires significant capital expenditures. Monitoring the company's debt-to-equity ratio quantifies the business's reliance on borrowed funds relative to its own equity. This metric compares total liabilities against the book value of shareholders' equity over time. An upward trend in the curve signals credit overheating and systemic risks, while a decrease in the ratio confirms financial stability and potential for stock growth.

Pesaing Insight Molecular Diagnostics

A - Utang-utang marang kapitalisasi buku|Rasio utang marang nilai buku questdiagnostics.com DGX|Illumina - Utang-utang marang kapitalisasi buku|EXAS: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku PerkinElmer|Bio-Rad Corp (BIO) - Rasio utang marang nilai buku|NNNN (Anbio Biotechnology) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku SHC|Rasio utang marang kapitalisasi buku QuidelOrtho Corporation (QDEL)|Rasio utang marang kapitalisasi buku OPKO Health Inc OPK|CDNA: Utang marang nilai buku|Maravai - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku FLGT (Fulgent Genetics, Inc.)|LAB - Utang-utang marang aset resik|Cytek Biosciences - Utang-utang marang kapitalisasi buku|OSUR (OraSure Technologies, Inc.) - Utang-utang marang aset resik|XGN: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik MDxHealth, Inc.|LUCD (Lucid Diagnostics Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik PRE (prenetics.com)|TRIB - Rasio utang marang kapitalisasi buku|ProPhase Labs Inc - Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku AIMD (Ainos Corp)|CODX - Utang-utang marang aset resik|Heart Test Laboratories - Utang-utang marang kapitalisasi buku|biomerica.com (BMRA) - Utang-utang marang aset resik|Cardio Diagnostics Holdings Inc. - Utang-utang marang kapitalisasi buku|Utang marang aset resik Virax Biolabs Group Limited|Bluejay (BJDX) - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik Aspira Women's Health Inc AWH|Utang marang nilai buku Accelerate Diagnostics (AXDX)|CNTG - Utang marang modal buku|Utang marang nilai buku Enzo (ENZ)|FRES: Rasio utang marang aset resik|GENE (gtglabs.com) - Rasio utang marang kapitalisasi buku|ME (23andMe Inc) - Utang marang nilai buku|Rasio utang marang kapitalisasi buku PMD (Psychemedics)